HSP90AA1 and metabolic disease: Network pharmacology prioritized STAT3, HSP90AA1, CASP3, CASP8, and SRC as core therapeutic targets, with molecular docking confirming stable interactions between these two metabolites and targets, highlighting their potential in managing infections, neoplasms, and metabolic disorders.